NASDAQ:ADIL

Adial Pharmaceuticals Stock Insider Trading

etoro logo Buy ADIL
*Your capital is at risk
$2.32
-0.0400 (-1.69%)
At Close: Jun 03, 2026

Adial Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 100.00. In total, the insiders bought 8.97M and sold 333.33K ADIL shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power

(Last 100 transactions)
100.00
Buy 8.97M shares
Sell 333.33K shares
98% Buy Activity
Moderate Negative Correlation

No Significant Signals

No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date Type Person Role Amount
Apr 07, 2026
Buy
Common Stock
A-Award
Claiborne Cary J
Chief Executive Officer
CEO / President 37 985
Value: $62.3K
Apr 07, 2026
Buy
Common Stock
A-Award
Gilliland Robertson H.
Director
Director 9 185
Value: $15.1K
Apr 07, 2026
Buy
Common Stock
A-Award
Shah Vinay
Chief Financial Officer
C-Suite Officer 17 325
Value: $28.4K
Apr 07, 2026
Buy
Common Stock
A-Award
Goodman Tony
Chief Operating Officer
C-Suite Officer 26 510
Value: $43.5K
Apr 07, 2026
Buy
Stock Option (Right to Buy)
A-Award
Anderson J. Kermit
Director
Director 9 185
Value: $15.1K
Apr 07, 2026
Buy
Common Stock
A-Award
Schuyler Kevin
Director
Director 9 185
Value: $15.1K
May 29, 2025
Buy
Stock Option (Right to Buy)
A-Award
Gilliland Robertson H.
Director
Director 28 000
Value: $19.3K
May 29, 2025
Buy
Stock Option (Right to Buy)
A-Award
Newman James W. Jr.
Director
Director 28 000
Value: $19.3K
May 29, 2025
Buy
Stock Option (Right to Buy)
A-Award
Shah Vinay
Chief Financial Officer
C-Suite Officer 9 000
Value: $6K
May 29, 2025
Buy
Stock Option (Right to Buy)
A-Award
Schuyler Kevin
Director
Director 28 000
Value: $19.3K
May 29, 2025
Buy
Stock Option (Right to Buy)
A-Award
Claiborne Cary J
Chief Executive Officer
CEO / President 138 000
Value: $94.9K
May 29, 2025
Buy
Stock Option (Right to Buy)
A-Award
Goodman Tony
Chief Operating Officer
C-Suite Officer 94 000
Value: $64.7K
May 29, 2025
Buy
Stock Option (Right to Buy)
A-Award
Anderson J. Kermit
Director
Director 28 000
Value: $19.3K
May 29, 2025
Buy
Stock Option (Right to Buy)
A-Award
Anderson J. Kermit
Director
Director 28 000
Value: $19.3K
May 29, 2025
Buy
Stock Option (Right to Buy)
A-Award
Goodman Tony
Chief Operating Officer
C-Suite Officer 94 000
Value: $64.7K
May 29, 2025
Buy
Stock Option (Right to Buy)
A-Award
Claiborne Cary J
Chief Executive Officer
CEO / President 138 000
Value: $94.9K
May 29, 2025
Buy
Stock Option (Right to Buy)
A-Award
Schuyler Kevin
Director
Director 28 000
Value: $19.3K
May 29, 2025
Buy
Stock Option (Right to Buy)
A-Award
Shah Vinay
Chief Financial Officer
C-Suite Officer 9 000
Value: $6K
May 29, 2025
Buy
Stock Option (Right to Buy)
A-Award
Newman James W. Jr.
Director
Director 28 000
Value: $19.3K
May 29, 2025
Buy
Stock Option (Right to Buy)
A-Award
Gilliland Robertson H.
Director
Director 28 000
Value: $19.3K
Dec 05, 2024
Buy
Stock Option (Right to Buy)
A-Award
Claiborne Cary J
Chief Executive Officer
CEO / President 350 000
Value: $402.5K
Dec 05, 2024
Buy
Stock Option (Right to Buy)
A-Award
Claiborne Cary J
Chief Executive Officer
CEO / President 350 000
Value: $402.5K
Nov 16, 2024
Buy
Stock Option
A-Award
Shah Vinay
Chief Financial Officer
C-Suite Officer 40 000
Value: $42.4K
Nov 16, 2024
Buy
Common Stock
J-Other
Shah Vinay
Officer
Officer 0
Value: $0
Nov 16, 2024
Buy
Common Stock
J-Other
Shah Vinay
Officer
Officer 0
Value: $0

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

Click to get the best stock tips daily for free!
ABOUT ADIAL PHARMACEUTICALS INC.
Adial Pharmaceuticals
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial...
GOLDEN STAR
Ticker Change Signal Date
LITE
$905.00
3.65% Jun 01
RUN
$12.83
15.74% May 06
GLBE
$31.61
0.569% May 05
SAP
$172.39
4.80% May 05
ADBE
$243.57
5.20% Apr 29

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE